BioArctic AB (publ) (BIOA-B) - Net Assets

Latest as of March 2026: Skr2.20 Billion SEK ≈ $236.54 Million USD

Based on the latest financial reports, BioArctic AB (publ) (BIOA-B) has net assets worth Skr2.20 Billion SEK (≈ $236.54 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr2.68 Billion ≈ $288.33 Million USD) and total liabilities (Skr481.21 Million ≈ $51.79 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of BioArctic AB (publ) to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr2.20 Billion
% of Total Assets 82.04%
Annual Growth Rate 33.63%
5-Year Change 149.42%
10-Year Change 3137.46%
Growth Volatility 283.23

BioArctic AB (publ) - Net Assets Trend (2015–2025)

This chart illustrates how BioArctic AB (publ)'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see BioArctic AB (publ) stock valuation.

Annual Net Assets for BioArctic AB (publ) (2015–2025)

The table below shows the annual net assets of BioArctic AB (publ) from 2015 to 2025. Also explore BIOA-B shareholders equity momentum to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2025-12-31 Skr1.97 Billion
≈ $211.69 Million		 +119.80%
2024-12-31 Skr894.94 Million
≈ $96.31 Million		 -14.49%
2023-12-31 Skr1.05 Billion
≈ $112.63 Million		 +33.11%
2022-12-31 Skr786.24 Million
≈ $84.61 Million		 -0.31%
2021-12-31 Skr788.68 Million
≈ $84.87 Million		 -13.07%
2020-12-31 Skr907.30 Million
≈ $97.64 Million		 -6.90%
2019-12-31 Skr974.50 Million
≈ $104.87 Million		 -4.25%
2018-12-31 Skr1.02 Billion
≈ $109.52 Million		 +59.99%
2017-12-31 Skr636.13 Million
≈ $68.46 Million		 +946.96%
2016-12-31 Skr60.76 Million
≈ $6.54 Million		 -43.89%
2015-12-31 Skr108.28 Million
≈ $11.65 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to BioArctic AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 1160.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings Skr1.35 Billion 68.70%
Common Stock Skr1.77 Million 0.09%
Other Comprehensive Income Skr772.00K 0.04%
Other Components Skr613.11 Million 31.17%
Total Equity Skr1.97 Billion 100.00%

BioArctic AB (publ) Competitors by Market Cap

The table below lists competitors of BioArctic AB (publ) ranked by their market capitalization.

Company Market Cap
Peab AB (publ)
ST:PEAB-B
 $2.54 Billion
Opendoor Technologies Inc
NASDAQ:OPEN
 $2.54 Billion
Hugo Boss AG
XETRA:BOSS
 $2.54 Billion
Chongqing Zongshen Power Machinery Co Ltd
SHE:001696
 $2.54 Billion
Attica Bank S.A.
AT:TATT
 $2.54 Billion
Hugo Boss AG
F:BOSA
 $2.54 Billion
Silvercorp Metals Inc
TO:SVM
 $2.54 Billion
Hawkins Inc
NASDAQ:HWKN
 $2.54 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in BioArctic AB (publ)'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 894,942,000 to 1,967,083,000, a change of 1,072,141,000 (119.8%).
  • Net income of 1,022,324,000 contributed positively to equity growth.
  • New share issuances of 26,014,000 increased equity.
  • Other comprehensive income decreased equity by 186,000.
  • Other factors increased equity by 23,989,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Skr1.02 Billion +51.97%
Share Issuances Skr26.01 Million +1.32%
Other Comprehensive Income Skr-186.00K -0.01%
Other Changes Skr23.99 Million +1.22%
Total Change Skr- 119.80%

Book Value vs Market Value Analysis

This analysis compares BioArctic AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 14.32x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 258.13x to 14.32x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2015-12-31 Skr1.23 Skr317.40 x
2016-12-31 Skr0.69 Skr317.40 x
2017-12-31 Skr7.22 Skr317.40 x
2018-12-31 Skr11.56 Skr317.40 x
2019-12-31 Skr11.07 Skr317.40 x
2020-12-31 Skr10.30 Skr317.40 x
2021-12-31 Skr8.96 Skr317.40 x
2022-12-31 Skr8.93 Skr317.40 x
2023-12-31 Skr11.83 Skr317.40 x
2024-12-31 Skr10.11 Skr317.40 x
2025-12-31 Skr22.17 Skr317.40 x

Capital Efficiency Dashboard

This dashboard shows how efficiently BioArctic AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 51.97%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 51.14%
  • • Asset Turnover: 0.78x
  • • Equity Multiplier: 1.31x
  • Recent ROE (51.97%) is above the historical average (16.10%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2015 3.43% 8.92% 0.32x 1.21x Skr-7.12 Million
2016 94.77% 54.52% 0.15x 11.65x Skr51.50 Million
2017 2.38% 10.77% 0.12x 1.79x Skr-48.46 Million
2018 37.50% 53.45% 0.51x 1.37x Skr279.83 Million
2019 9.08% 31.40% 0.24x 1.21x Skr-8.98 Million
2020 -7.55% -109.90% 0.06x 1.16x Skr-159.25 Million
2021 -15.19% -517.54% 0.03x 1.14x Skr-198.66 Million
2022 -1.42% -4.90% 0.27x 1.09x Skr-89.80 Million
2023 21.90% 37.22% 0.52x 1.13x Skr124.59 Million
2024 -19.79% -68.81% 0.23x 1.24x Skr-266.57 Million
2025 51.97% 51.14% 0.78x 1.31x Skr825.62 Million

Industry Comparison

This section compares BioArctic AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $262,534,602
  • Average return on equity (ROE) among peers: -100.66%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
BioArctic AB (publ) (BIOA-B) Skr2.20 Billion 3.43% 0.22x $2.54 Billion
2cureX AB (2CUREX) $5.10 Million -80.96% 0.52x $1.13 Million
Ascelia Pharma AB (publ) (ACE) $236.06 Million -41.81% 0.08x $8.49 Million
AcouSort AB (ACOU) $24.14 Million -70.81% 0.43x $6.06 Million
Active Biotech AB (ACTI) $678.78 Million 4.86% 0.10x $11.36 Million
Alzinova AB (ALZ) $947.42K -195.83% 0.18x $10.01 Million
AlzeCure Pharma (ALZCUR) $26.18 Million -134.56% 0.32x $98.93 Million
Annexin Pharmaceuticals AB (ANNX) $13.71 Million -366.46% 0.39x $9.79 Million
Alligator Bioscience AB (ATORX) $10.91 Million 0.00% 0.59x $2.23 Million
BioInvent International AB (BINV) $1.37 Billion -20.41% 0.06x $160.04 Million

About BioArctic AB (publ)

ST:BIOA-B Sweden Biotechnology
Market Cap
$2.54 Billion
Skr23.59 Billion SEK
Market Cap Rank
#5406 Global
#73 in Sweden
Share Price
Skr317.40
Change (1 day)
-2.46%
52-Week Range
Skr263.60 - Skr364.40
All Time High
Skr377.80
Categories
Companies in Sweden Biotechnology
About

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other ALS diseases. In addition, it offers L… Read more